Obsessive-compulsive disorder is common, persistent (in the absence of therapy), and oftentimes disabling. About 30-40% of patients fail to respond sufficiently to first line treatments of exposure and response prevention (ERP) and serotonin reuptake inhibitors (SRIs). Adjunctive antipsychotics are the only established second line pharmacological approach. Join Wayne Goodman, MD, as he reviews the literature outcomes with DBS, discusses inclusion/exclusion criteria for implanted devices and surgical procedures, as well as sharing his experience with conducting DBS programming.
- Obsessive-Compulsive Disorder
- Live Webinar
- ACEP NBCC clock hours
- AMA PRA Category 1 Credit™
- Category I credits for Social Workers
- MNA Contact Hours for Nurses
Event date October 12, 2022